Blood Cancers | Tumor

Bexobrutideg Receives Orphan Drug Designation in Waldenström Macroglobulinemia

March 17th 2025, 7:00pm

Article

Bexobrutideg, a bioavailable agent, was granted orphan drug designation by the FDA for Waldenström macroglobulinemia, a type of non-Hodgkin's lymphoma.

A Picture is Worth Ten Thousand Words When it Comes to Cancer

March 17th 2025, 5:00pm

Article

Years after losing my brother to Hodgkin’s lymphoma, I learned something about how he felt facing a terminal diagnosis by studying an old Polaroid.

Bringing Together the CAR T-Cell Therapy Community

March 12th 2025, 7:26pm

Article

It’s easy to think of scientific researchers as existing in a vacuum.

Nutrition is Key Following a Cancer Diagnosis

March 12th 2025, 7:14pm

Article

Nutrition is a challenge for many patients with cancer.

The Leukemia & Lymphoma Society is Helping Patients With Medial Debt

March 12th 2025, 7:01pm

Article

Cancer is one of the most expensive medical conditions to treat in the U.S.

JAK Inhibitors Reduce Thromboembolic Risk in Myeloproliferative Neoplasm Therapy

March 11th 2025, 3:38pm

Article

JAK inhibitor treatment is associated with a reduction in risk of thromboembolic events for patients with myeloproliferative neoplasms.

FDA Accepts Ordspono Resubmission in R/R Follicular Lymphoma Treatment

March 3rd 2025, 4:00pm

Article

The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.

Cema-Cel Has Durable Responses in in Relapsed/Refractory Large B-Cell Lymphoma

February 28th 2025, 10:00pm

Article

Treatment with the CAR T-cell therapy cema-cel demonstrated durable responses in patients with relapsed/refractory large B-cell lymphoma.

A Study Investigates If CAR T Therapy Directly Causes Secondary Malignancies

February 26th 2025, 8:00pm

Video

There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.

The FDA Grants ODD to OPN-6602 For Relapsed/Refractory Myeloma

February 18th 2025, 4:00pm

Article

The FDA has granted orphan drug designation to the oral agent OPN-6602 for the treatment of patients with relapsed or refractory multiple myeloma.